Last $2.18 USD
Change Today -0.04 / -1.80%
Volume 207.1K
ANTH On Other Exchanges
As of 8:10 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

anthera pharmaceuticals inc (ANTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/13 - $4.26
52 Week Low
09/15/14 - $2.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

anthera pharmaceuticals inc (ANTH) Related Bloomberg News

View More Bloomberg News

anthera pharmaceuticals inc (ANTH) Related Businessweek News

No Related Businessweek News Found

anthera pharmaceuticals inc (ANTH) Details

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. It is developing blisibimod, a Phase III product candidate that targets elevated levels of B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. The company was founded in 2004 and is headquartered in Hayward, California.

25 Employees
Last Reported Date: 03/28/14
Founded in 2004

anthera pharmaceuticals inc (ANTH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $577.3K
Senior Vice President of Finance & Administra...
Total Annual Compensation: $224.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $350.0K
Chief Technology Officer and Senior Vice Pres...
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2013.

anthera pharmaceuticals inc (ANTH) Key Developments

Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Anthera Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $6,865,000 against $6,953,000 a year ago. Net loss was $7,256,000 against $8,281,000 a year ago. The decrease in net loss is a direct result of a decrease in interest expense in the current period. Basic and diluted net loss per share was $0.34 against $0.43 a year ago. For the six months, the company reported loss from operations of $14,474,000 against $13,854,000 a year ago. Net loss was $15,172,000 against $15,861,000 a year ago. The decrease in net loss is mainly due to a decrease in interest expense by $1.4 million, offset by an increase in research and development expense of $0.9 million. Basic and diluted net loss per share was $0.73 against $0.92 a year ago.

Anthera Pharmaceuticals, Inc. Announces the Appointment of Chuck Olson as President

Anthera Pharmaceuticals, Inc. announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy from Eli Lilly and Company. Concurrent with the transaction, Anthera announced the appointment of Chuck Olson, D.Sc. as President of Alkira. Dr. Olson will oversee development activities for Sollpura including product manufacturing for the upcoming phase 3 clinical trial to begin in mid 2015.

Anthera Pharmaceuticals, Inc., Eli Lilly and Company - M&A Call

To consider the acquisition between Anthera Pharmaceuticals, Inc. and Eli Lilly and Company


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTH:US $2.18 USD -0.04

ANTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation ANTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTHERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at